Latest Period
Q1 2026
Security Snapshot
ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) Institutional Ownership
CUSIP: 02043Q107
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
786
Shares (Excl. Options)
130,099,261
Price
$330.87
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ALNY on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 130,099,261
- Total 13F value
- $42,944,390,173
- Portfolio coverage rank
- 0.01%
- Share change
- -129,961
- Value change
- -$452,778,395
- Number of holders
- 786
- Shares outstanding
- 133,131,695
- SEC-reported price per share
- $301.03
- Insider filing price
- $301.03
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 02043Q107.
- 786 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 786 to 193 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $42,944,390,173 to $498,008,653.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 786 institutions filings for Q1 2026.
Security key
02043Q107
Latest holder period
Q1 2026
13F holders
786
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
ALNY full holder history
ALNYLAM PHARMACEUTICALS, INC. SEC filings
ALNYLAM PHARMACEUTICALS, INC. company facts
ALNYLAM PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 02043Q107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ALNY
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | -14% | $4,875,294,782 | -$730,458,810 | 14,640,525 | -13% | FMR LLC | 31 Mar 2026 |
| Capital World Investors | 8.2% | $3,635,294,067 | 10,916,799 | Capital World Investors | 31 Mar 2026 | |||
| Capital Research Global Investors | 7.1% | +34% | $3,153,903,273 | +$833,388,444 | 9,471,181 | +36% | Capital Research Global Investors | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4% | $2,350,677,826 | 7,104,536 | Vanguard Capital Management | 31 Mar 2026 |
As of 31 Mar 2026, 786 institutional investors reported holding 130,099,261 shares of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY). This represents 98% of the company’s total 133,131,695 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 14,579,166 | -8.3% | 0.25% | $4,823,808,693 |
| Capital World Investors | 8.1% | 10,802,348 | -34% | 0.49% | $3,573,758,048 |
| BlackRock, Inc. | 7.8% | 10,444,908 | +0.42% | 0.06% | $3,455,906,710 |
| Capital Research Global Investors | 7.1% | 9,471,181 | +40% | 0.49% | $3,133,497,254 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.9% | 6,491,280 | 0% | 0.11% | $2,147,769,814 |
| JPMORGAN CHASE & CO | 4.7% | 6,323,752 | +34% | 0.14% | $1,998,875,417 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 5,946,706 | 0% | 0.05% | $1,967,586,614 |
| T. Rowe Price Investment Management, Inc. | 3.9% | 5,193,324 | +196% | 1.2% | $1,718,316,000 |
| STATE STREET CORP | 2.5% | 3,322,698 | +2.9% | 0.04% | $1,099,381,087 |
| Invesco Ltd. | 2.1% | 2,783,394 | -6.2% | 0.12% | $920,941,573 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,660,385 | +0.36% | 0.06% | $884,565,832 |
| BAILLIE GIFFORD & CO | 1.9% | 2,493,866 | -4.1% | 0.84% | $825,145,443 |
| TWO SIGMA INVESTMENTS, LP | 1.5% | 1,992,577 | +223% | 0.55% | $659,283,952 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.5% | 1,935,925 | +19% | 0.12% | $640,539,505 |
| Dodge & Cox | 1.4% | 1,929,253 | -1.8% | 0.35% | $638,331,940 |
| AMERICAN CENTURY COMPANIES INC | 1.4% | 1,802,363 | +21% | 0.31% | $596,349,775 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.1% | 1,432,748 | -16% | 0.05% | $474,055,000 |
| Clearbridge Investments, LLC | 1% | 1,356,036 | +127% | 0.39% | $448,671,479 |
| Orbis Allan Gray Ltd | 1% | 1,334,825 | -18% | 1.9% | $441,653,547 |
| MARSHALL WACE, LLP | 0.83% | 1,099,318 | +100% | 0.39% | $363,731,347 |
| D. E. Shaw & Co., Inc. | 0.8% | 1,059,062 | +138% | 0.28% | $350,411,844 |
| MORGAN STANLEY | 0.75% | 1,002,681 | +3.4% | 0.02% | $331,758,096 |
| BANK OF AMERICA CORP /DE/ | 0.73% | 966,912 | +41% | 0.02% | $319,922,242 |
| Legal & General Group Plc | 0.7% | 934,881 | -2.8% | 0.07% | $309,324,079 |
| AQR CAPITAL MANAGEMENT LLC | 0.69% | 913,104 | -0.75% | 0.14% | $297,872,637 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q1 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 1,661,541 | $498,008,653 | +$24,449,784 | $301.03 | 193 |
| 2026 Q1 | 130,099,261 | $42,944,390,173 | -$452,778,395 | $330.87 | 786 |
| 2025 Q4 | 129,488,819 | $51,507,210,845 | -$543,273,038 | $397.65 | 845 |
| 2025 Q3 | 129,757,754 | $59,159,078,884 | -$749,369,667 | $456.00 | 814 |
| 2025 Q2 | 132,062,946 | $43,060,444,035 | +$1,728,282,756 | $326.09 | 645 |
| 2025 Q1 | 126,881,187 | $34,233,011,857 | -$90,968,751 | $270.02 | 615 |
| 2024 Q4 | 127,632,870 | $30,037,175,866 | -$216,265,374 | $235.31 | 587 |
| 2024 Q3 | 123,754,217 | $34,035,461,284 | +$1,116,635,795 | $275.03 | 559 |
| 2024 Q2 | 119,818,858 | $29,121,298,158 | +$1,425,600,934 | $243.00 | 514 |
| 2024 Q1 | 114,506,382 | $17,112,788,490 | -$462,345,987 | $149.45 | 488 |
| 2023 Q4 | 117,037,909 | $22,406,153,370 | -$144,088,009 | $191.41 | 491 |
| 2023 Q3 | 117,774,911 | $20,850,702,200 | -$144,549,642 | $177.10 | 445 |
| 2023 Q2 | 118,559,398 | $22,525,153,339 | -$212,624,410 | $189.94 | 469 |
| 2023 Q1 | 119,657,504 | $23,956,079,414 | +$6,809,245 | $200.32 | 469 |
| 2022 Q4 | 119,654,959 | $28,425,215,078 | -$3,086,850,614 | $237.65 | 477 |
| 2022 Q3 | 133,393,008 | $26,709,327,641 | +$3,401,526,639 | $200.16 | 479 |
| 2022 Q2 | 113,477,846 | $16,543,858,767 | -$67,066,647 | $145.85 | 405 |
| 2022 Q1 | 113,908,234 | $18,598,579,814 | +$320,228,126 | $163.29 | 417 |
| 2021 Q4 | 112,006,374 | $18,989,908,067 | +$63,928,357 | $169.58 | 420 |
| 2021 Q3 | 111,604,687 | $21,068,206,424 | -$147,043,437 | $188.81 | 395 |
| 2021 Q2 | 112,239,402 | $19,027,485,774 | +$501,915,844 | $169.52 | 390 |
| 2021 Q1 | 109,361,699 | $15,431,272,628 | +$204,818,578 | $141.19 | 381 |
| 2020 Q4 | 107,900,409 | $14,018,800,907 | -$114,208,967 | $129.97 | 353 |
| 2020 Q3 | 108,499,178 | $15,789,451,789 | -$460,283,345 | $145.60 | 347 |
| 2020 Q2 | 111,562,100 | $16,522,566,788 | +$489,977,680 | $148.11 | 363 |